Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	₩1,705.00	+0.77%	14,548
13/26/13	₩1,692.00	+0.06%	3,344
12/26/12	₩1,691.00	-0.59%	2,679
11/26/11	₩1,701.00	+0.95%	6,356
10/26/10	₩1,685.00	+0.66%	3,930

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
1,705.00 ^KRW	+0.77%		+1.85%	-65.90%

01/07	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
26/05	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Market Cap	1.88TCr 1.33Cr 1.15Cr 1.08Cr 98.27L 1.85Cr 127.31Cr 1.88Cr 13Cr 4.95Cr 64Cr 5Cr 4.89Cr 211.85Cr	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	162.7Cr 11.51L 10L 9L 8L 15.97L 11Cr 16.24L 1.09Cr 42.8L 5.51Cr 43.21L 42.28L 18Cr	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

01/07	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
26/05	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
14/05	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
07/05	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
28/04	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
28/04	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
20/03	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
16/03	APTOCROM Inc. announces Annual dividend	CI
13/11	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/25/13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25/25/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
22/25/22	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	+0.77%
1 week	+1.85%
Current month	+2.34%
1 month	+0.35%
3 months	-44.28%
6 months	-57.59%
Current year	-65.90%

APTOCROM Inc. Share Price

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,620	1,740
1 month	1,430	1,740
Current year	1,430	5,400
1 year	1,430	8,740
3 years	1,430	42,300
5 years	1,430	1,13,000
10 years	1,430	4,26,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	23/03/2022
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	23/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	10/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+0.77%	+1.85%	-79.11%	-95.48%	1.33Cr
ELI LILLY AND COMPANY	+1.34%	-3.02%	+71.15%	+122.21%	1,05200Cr
JOHNSON & JOHNSON	+1.35%	+0.59%	+49.42%	+51.35%	63TCr
ABBVIE INC.	+0.50%	+1.06%	+21.31%	+67.04%	44TCr
ROCHE HOLDING AG	+0.28%	-4.56%	+39.10%	+38.05%	35TCr
NOVARTIS AG	+0.78%	-2.68%	+23.13%	+37.32%	29TCr
ASTRAZENECA PLC	+0.87%	-3.59%	-1.52%	+7.12%	24TCr
AMGEN INC.	+0.81%	+0.15%	+42.79%	+58.36%	22TCr
NOVO NORDISK A/S	-0.78%	-4.49%	-15.86%	-54.13%	20TCr
GILEAD SCIENCES, INC.	+0.33%	+4.03%	+17.32%	+80.94%	17TCr
Average	+0.49%	-0.58%	+16.78%	+31.28%	35.95TCr
Weighted average by Cap.	+0.72%	-0.63%	+40.21%	+64.56%

	2024	2025
Net sales	1.64TCr 1.16Cr 1Cr 94.16L 85.64L 1.61Cr 110.94Cr 1.64Cr 11Cr 4.31Cr 56Cr 4.36Cr 4.26Cr 184.62Cr	980.73Cr 69.38L 59.92L 56.31L 51.21L 96.28L 66Cr 97.87L 6.6Cr 2.58Cr 33Cr 2.6Cr 2.55Cr 110.4Cr
Net income	-2.81TCr -1.99Cr -1.72Cr -1.61Cr -1.47Cr -2.76Cr -190.05Cr -2.8Cr -19Cr -7.39Cr -95Cr -7.46Cr -7.3Cr -316.26Cr	-555.94Cr -39.33L -33.97L -31.92L -29.03L -54.58L -38Cr -55.48L -3.74Cr -1.46Cr -19Cr -1.48Cr -1.44Cr -63Cr
Net Debt	-2.51TCr -1.77Cr -1.53Cr -1.44Cr -1.31Cr -2.46Cr -169.57Cr -2.5Cr -17Cr -6.59Cr -85Cr -6.66Cr -6.51Cr -282.19Cr	-1.72TCr -1.22Cr -1.05Cr -98.71L -89.77L -1.69Cr -116.3Cr -1.72Cr -12Cr -4.52Cr -58Cr -4.57Cr -4.47Cr -193.54Cr